BETA


1998/0240(COD) Orphan medicinal products

Progress: Procedure completed

RoleCommitteeRapporteurShadows
Lead ENVI GROSSETÊTE Françoise (icon: PPE-DE PPE-DE)
Former Responsible Committee ENVI CABROL Christian E.A. (icon: UFE UFE)
Former Committee Opinion ENER SCAPAGNINI Umberto (icon: PPE PPE)
Former Committee Opinion BUDG
Former Committee Opinion DEVE ROCARD Michel (icon: PES PES)
Lead committee dossier:
Legal Basis:
EC Treaty (after Amsterdam) EC 095

Events

2020/08/11
   EC - Follow-up document
Documents
2020/08/11
   EC - Follow-up document
2016/01/26
   EC - Follow-up document
Details

This Commission staff working document concerns the fourth inventory of Union and Member State incentives to support research into, and the development and availability of, orphan medicinal products — state of play 2015.

This year marks the 15th anniversary of the Orphan Regulation . In that time, there has been impressive progress , in particular as regards generating significant activity by the pharmaceutical industry in this field.

After 15 years of implementation and significant advances for patients, the Commission wishes now to take stock of progress in this field.

This paper thus represents the fourth version of the inventory.

Main conclusions : the Commission has launched a survey to collect information on national measures to support research into, and the development and availability of, OMPs. This information was based on Member States information validated by the relevant national competent authorities in December 2015. The Commission cannot vouch for its accuracy or completeness.

R&D support : some Member States have introduced reduced fees for registration and academic clinical trials, tax reductions or waivers, public funding for research and free scientific advice.

In France , OMP developers are exempt from certain taxes to be paid by pharmaceutical companies. In the Netherlands , the registration fee can be waived if the medicinal product is already registered in one or more other Member State and the prevalence of the condition is less than 1:150 000. Poland and the United Kingdom , on the other hand, have no specific measures for orphan medicinal products either.

Availability of OMPs to patients : as regards measures to support the availability of OMPs to patients, many Member States have confirmed that they are implementing ‘compassionate-use’ programmes to bring unauthorised medicinal products to market. Such programmes are used for individual patients (‘patient programmes’) on the basis of a doctor’s statement or the company can make products available to a group of patients.

Reimbursement of the product : the cost of the product may or may not be reimbursed, depending on the Member State. In Greece for instance, orphan drugs covered by a compassionate-use programme for individual patients are reimbursed in full. In Germany , all OMPs are reimbursed directly after market authorisation.

The impact of reimbursement on the availability of orphan medicinal products may be a matter of concern in the EU. The budgetary impact of OMPs is expected to rise due to the newly authorised products in the coming years. In this context, it is important to highlight that some Member States have adopted specific measures for the reimbursement of OMPs.

Other measures : most Member States reported other measures that they have taken under national plans on rare diseases that cover not only OMPs, but also the prevention (e.g. pre-natal diagnosis) and detection of rare diseases, the exchange of information and cooperation with patients’ organisations. In this context, most confirmed progress for the implementation of the Orphanet database and of centres of expertise for rare diseases and had registers of patients with particular diseases.

Documents
2006/06/20
   EC - Follow-up document
Details

This Commission staff working document sets out the experience required as a result of the application of Regulation 141/2000/EC on orphan medicinal products and account of the public health benefits obtained.

Orphan medicinal products are intended for the diagnosis, prevention or treatment of life-threatening or very rare serious conditions.

The report states that the response to the orphan legislation in the EU has far exceeded initial expectations; more than 450 applications have been submitted in the period between April 2000 and April 2005. Of those, more than 260 have been designated and 2 have gone on to receive a marketing authorisation.

Although more than 5 years of experience with the Regulation has now been gained, the true impact of the EU orphan initiative on public health will only be revealed progressively as longer term experience is accumulated. Already, more than 1 million patients suffering from orphan diseases in the Community may potentially benefit from these new 22 orphan medicines authorised during the first 5 years of application of Regulation 141/2000/EC. In addition, there is good ground to assume that the legislation has stimulated industrial activity leading to company creation with promising high-tech potential.

The full benefits of the EU orphan regulations require optimal synergies between action on Community and on Member State level. Incentives at the European Union level need to be translated into rapid access for patients to the new products throughout the entire Community and they need to be supplemented by incentives at Member States level. In this regard, the past experience was not entirely satisfactory.

2000/01/22
   Final act published in Official Journal
1999/12/16
   CSL - Final act signed
1999/12/16
   EP - End of procedure in Parliament
1999/12/15
   EP - Text adopted by Parliament, 2nd reading
1999/12/15
   EP - Decision by Parliament, 2nd reading
Documents
1999/11/25
   EP - Committee recommendation tabled for plenary, 2nd reading
1999/11/25
   EP - Vote in committee, 2nd reading
1999/11/24
   EP - Committee recommendation tabled for plenary, 2nd reading
Documents
1999/10/07
   EP - Committee referral announced in Parliament, 2nd reading
1999/10/01
   EC - Commission communication on Council's position
1999/09/27
   CSL - Council position
1999/09/27
   CSL - Council Meeting
1999/09/26
   CSL - Council position published
Documents
1999/09/02
   EP - GROSSETÊTE Françoise (PPE-DE) appointed as rapporteur in ENVI
1999/06/21
   CSL - Council Meeting
1999/06/15
   EC - Modified legislative proposal
1999/06/14
   EC - Modified legislative proposal published
1999/03/09
   EP - Text adopted by Parliament, 1st reading/single reading
1999/03/09
   EP - Debate in Parliament
1999/03/09
   EP - Decision by Parliament, 1st reading
Documents
1999/02/18
   EP - Committee report tabled for plenary, 1st reading/single reading
1999/02/18
   EP - Vote in committee, 1st reading
1999/02/17
   EP - Committee report tabled for plenary, 1st reading
Documents
1999/01/27
   ESC - Economic and Social Committee: opinion, report
1998/10/28
   EP - SCAPAGNINI Umberto (PPE) appointed as rapporteur in ENER
1998/10/28
   EP - ROCARD Michel (PES) appointed as rapporteur in DEVE
1998/09/22
   EP - CABROL Christian E.A. (UFE) appointed as rapporteur in ENVI
1998/09/14
   EP - Committee referral announced in Parliament, 1st reading
1998/07/27
   EC - Legislative proposal
1998/07/26
   EC - Legislative proposal published
1995/11/30
   CSL - Resolution/conclusions adopted by Council
Details

‘The Council of the European Union, having regard to the Treaty establishing the European Community; whereas, in its Resolution of 30 November 1995 on the integration of health protection requirements in Community policies, the Council considers that the Community must pay particular attention to the impact on health of action proposed in a number of areas, including free movement of goods; whereas action to improve understanding of and address the impact on human health of the free movement of goods, in particular the free movement of medicinal products, should form part of the Community’s overall strategy for action in the field of public health; whereas there are many diseases from which small numbers of people suffer in the Member States and across the Community as a whole; whereas steps are needed to make it easier for patients suffering from those diseases to have access to treatments, in particular by means of so­-called ‘orphan’ drugs, meeting the same criteria as all medicines; whereas, despite the relative infrequency of such diseases, the nature of their treatment and their particular health, economic and social effects are such as to make it advisable to consider them in a European context; whereas the Commission, in its communication of 24 November 1993 on the framework for action in the field for public health, singled out rare diseases as one of eight priority areas for Community action; whereas, in its Decision of 15 December 1994 adopting a specific programme of research and technological development, including demonstration, in the field of biomedicine and health (1994 to 1998), the Council specified rare diseases and orphan drugs as a specific research area (area 4.6), with actions including an inventory of rare disorders; whereas the Commission in its communication of 2 March 1994 on the outlines of an industrial policy for the pharmaceutical sector in the European Community referred to the work to be undertaken, within the field of research on biomedicine and health, on orphan drugs, where research may not be commercially viable; whereas there are certain drugs which are already marketed and have low commercial interest but are of major importance for the treatment of some rare diseases; whereas a common European approach to rare diseases and orphan drugs holds out advantages in epidemiological, public health and economic terms, CALLS ON the Commission, in close cooperation with the Member States and in the light of the guidelines in the Annex, to look into the situation of orphan drugs in Europe and, if necessary, make appropriate proposals with a view to improving access to medicinal products intended particularly for people suffering from rare diseases. Annex Aspects to be considered 1) The definition of an ‘orphan drug’; 2) The definition of a ‘rare disease’, having regard to its prevalence; 3) The criteria for obtaining ‘orphan drug’ status in Europe, establishing conditions for drugs’ inclusion or exclusion, in the light of any changes in the conditions on the basis of which they were classified; 4) Measures using regulatory provisions (including intellectual property aspects) and financial incentives to promote research, development, marketing authorisation and distribution of orphan drugs; 5) Examination of the health impact of a European policy on orphan drugs in the Member States and its economic impact for European industry.’

1995/11/30
   CSL - Council Meeting

Documents

History

(these mark the time of scraping, not the official date of the change)

docs/0/docs/1/url
Old
https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:C:1998:276:TOC
New
https://eur-lex.europa.eu/JOHtml.do?uri=OJ:C:1998:276:SOM:EN:HTML
docs/1
date
1999-01-27T00:00:00
docs
type
Economic and Social Committee: opinion, report
body
ESC
docs/1
date
1998-12-08T00:00:00
docs
title: PE228.612/DEF
committee
BUDG
type
Committee opinion
body
EP
docs/1/docs/1/url
Old
https://eur-lex.europa.eu/JOHtml.do?uri=OJ:C:1999:101:SOM:EN:HTML
New
https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:C:1999:101:TOC
docs/2
date
1999-01-13T00:00:00
docs
title: PE229.051
type
Committee draft report
body
EP
docs/3
date
1999-03-09T00:00:00
docs
summary
type
Text adopted by Parliament, 1st reading/single reading
body
EP
docs/3
date
1999-01-21T00:00:00
docs
title: PE228.204/DEF
committee
DEVE
type
Committee opinion
body
EP
docs/3/docs/0/url
Old
https://eur-lex.europa.eu/JOHtml.do?uri=OJ:C:1999:175:SOM:EN:HTML
New
https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:C:1999:175:TOC
docs/4
date
1999-01-27T00:00:00
docs
type
Economic and Social Committee: opinion, report
body
ESC
docs/5
date
1999-02-03T00:00:00
docs
title: PE229.051/AM
type
Amendments tabled in committee
body
EP
docs/6
date
1999-02-04T00:00:00
docs
title: PE228.976/DEF
committee
ENER
type
Committee opinion
body
EP
docs/8
date
1999-03-09T00:00:00
docs
summary
type
Text adopted by Parliament, 1st reading/single reading
body
EP
docs/8
date
1999-12-15T00:00:00
docs
summary
type
Text adopted by Parliament, 2nd reading
body
EP
docs/8/docs/1/url
Old
https://eur-lex.europa.eu/JOHtml.do?uri=OJ:C:2000:296:SOM:EN:HTML
New
https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:C:2000:296:TOC
docs/9
date
2006-06-20T00:00:00
docs
summary
type
Follow-up document
body
EC
docs/9/docs/0/url
Old
http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/sec/2006/0832/COM_SEC(2006)0832_EN.pdf
New
http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/sec/2006/0832/COM_SEC(2006)0832_EN.pdf
docs/12
date
1999-11-17T00:00:00
docs
title: PE231.753
type
Committee draft report
body
EP
docs/14
date
1999-12-15T00:00:00
docs
summary
type
Text adopted by Parliament, 2nd reading
body
EP
docs/15
date
2006-06-20T00:00:00
docs
summary
type
Follow-up document
body
EC
events/1/date
Old
1998-07-27T00:00:00
New
1998-07-26T00:00:00
events/4/date
Old
1999-02-18T00:00:00
New
1999-02-17T00:00:00
events/7/date
Old
1999-06-15T00:00:00
New
1999-06-14T00:00:00
events/8/date
Old
1999-09-27T00:00:00
New
1999-09-26T00:00:00
events/11/date
Old
1999-11-25T00:00:00
New
1999-11-24T00:00:00
docs/4
date
1999-01-27T00:00:00
docs
type
Economic and Social Committee: opinion, report
body
ESC
docs/4
date
1999-01-27T00:00:00
docs
type
Economic and Social Committee: opinion, report
body
ESC
docs/7/docs/0/url
Old
http://www.europarl.europa.eu/doceo/document/A-4-1999-0078_EN.html
New
https://www.europarl.europa.eu/doceo/document/A-4-1999-0078_EN.html
docs/13/docs/0/url
Old
http://www.europarl.europa.eu/doceo/document/A-5-1999-0080_EN.html
New
https://www.europarl.europa.eu/doceo/document/A-5-1999-0080_EN.html
docs/14
date
1999-12-15T00:00:00
docs
summary
type
Text adopted by Parliament, 2nd reading
body
EP
docs/14
date
1999-12-15T00:00:00
docs
summary
type
Text adopted by Parliament, 2nd reading
body
EP
docs/15/docs/0/url
Old
http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/sec/2006/0832/COM_SEC(2006)0832_EN.pdf
New
http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/sec/2006/0832/COM_SEC(2006)0832_EN.pdf
docs/17
date
2020-08-11T00:00:00
docs
title: SWD(2020)0163
type
Follow-up document
body
EC
docs/18
date
2020-08-11T00:00:00
docs
type
Follow-up document
body
EC
events/2/type
Old
Committee referral announced in Parliament, 1st reading/single reading
New
Committee referral announced in Parliament, 1st reading
events/3/type
Old
Vote in committee, 1st reading/single reading
New
Vote in committee, 1st reading
events/4
date
1999-02-18T00:00:00
type
Committee report tabled for plenary, 1st reading
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/A-4-1999-0078_EN.html title: A4-0078/1999
events/4
date
1999-02-18T00:00:00
type
Committee report tabled for plenary, 1st reading/single reading
body
EP
docs
url: http://www.europarl.europa.eu/doceo/document/A-4-1999-0078_EN.html title: A4-0078/1999
events/5/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=19990309&type=CRE
New
https://www.europarl.europa.eu/doceo/document/EN&reference=19990309&type=CRE
events/6/type
Old
Decision by Parliament, 1st reading/single reading
New
Decision by Parliament, 1st reading
events/11/docs/0/url
Old
http://www.europarl.europa.eu/doceo/document/A-5-1999-0080_EN.html
New
https://www.europarl.europa.eu/doceo/document/A-5-1999-0080_EN.html
events/12/docs/0/url
Old
http://www.europarl.europa.eu/doceo/document/TA-5-1999-0148_EN.html
New
https://www.europarl.europa.eu/doceo/document/TA-5-1999-0148_EN.html
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Environment, Public Health, Consumer Policy
committee
ENVI
rapporteur
name: GROSSETÊTE Françoise date: 1999-09-02T00:00:00 group: European People's Party (Christian Democrats) and European Democrats abbr: PPE-DE
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Environment, Public Health, Consumer Policy
committee
ENVI
date
1999-09-02T00:00:00
rapporteur
name: GROSSETÊTE Françoise group: European People's Party (Christian Democrats) and European Democrats abbr: PPE-DE
committees/1
type
Former Responsible Committee
body
EP
associated
False
committee_full
Environment, Public Health and Consumer Protection
committee
ENVI
rapporteur
name: CABROL Christian E.A. date: 1998-09-22T00:00:00 group: Union for Europe Group abbr: UFE
committees/1
type
Former Responsible Committee
body
EP
associated
False
committee_full
Environment, Public Health and Consumer Protection
committee
ENVI
date
1998-09-22T00:00:00
rapporteur
name: CABROL Christian E.A. group: Union for Europe Group abbr: UFE
committees/2/date
    committees/3
    type
    Former Committee Opinion
    body
    EP
    associated
    False
    committee_full
    Research, Technological Development and Energy
    committee
    ENER
    rapporteur
    name: SCAPAGNINI Umberto date: 1998-10-28T00:00:00 group: European People's Party (Christian Democrats) abbr: PPE
    committees/3
    type
    Former Committee Opinion
    body
    EP
    associated
    False
    committee_full
    Research, Technological Development and Energy
    committee
    ENER
    date
    1998-10-28T00:00:00
    rapporteur
    name: SCAPAGNINI Umberto group: European People's Party (Christian Democrats) abbr: PPE
    committees/4
    type
    Former Committee Opinion
    body
    EP
    associated
    False
    committee_full
    Development and Cooperation
    committee
    DEVE
    rapporteur
    name: ROCARD Michel date: 1998-10-28T00:00:00 group: Party of European Socialists abbr: PES
    committees/4
    type
    Former Committee Opinion
    body
    EP
    associated
    False
    committee_full
    Development and Cooperation
    committee
    DEVE
    date
    1998-10-28T00:00:00
    rapporteur
    name: ROCARD Michel group: Party of European Socialists abbr: PES
    docs/0/docs/1/url
    Old
    https://eur-lex.europa.eu/JOHtml.do?uri=OJ:C:1998:276:SOM:EN:HTML
    New
    https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:C:1998:276:TOC
    docs/4/docs/1/url
    Old
    https://eur-lex.europa.eu/JOHtml.do?uri=OJ:C:1999:101:SOM:EN:HTML
    New
    https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:C:1999:101:TOC
    docs/7
    date
    1999-02-18T00:00:00
    docs
    type
    Committee report tabled for plenary, 1st reading/single reading
    body
    EP
    docs/7
    date
    1999-02-18T00:00:00
    docs
    type
    Committee report tabled for plenary, 1st reading/single reading
    body
    EP
    docs/8/docs/0/url
    Old
    https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:C:1999:175:TOC
    New
    https://eur-lex.europa.eu/JOHtml.do?uri=OJ:C:1999:175:SOM:EN:HTML
    docs/13/docs/0/url
    Old
    http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A5-1999-80&language=EN
    New
    http://www.europarl.europa.eu/doceo/document/A-5-1999-0080_EN.html
    docs/14
    date
    1999-12-15T00:00:00
    docs
    summary
    type
    Text adopted by Parliament, 2nd reading
    body
    EP
    docs/14
    date
    1999-12-15T00:00:00
    docs
    summary
    type
    Text adopted by Parliament, 2nd reading
    body
    EP
    docs/15/docs/0/url
    Old
    http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/sec/2006/0832/COM_SEC(2006)0832_EN.pdf
    New
    http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/sec/2006/0832/COM_SEC(2006)0832_EN.pdf
    events/4/docs/0/url
    Old
    http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A4-1999-78&language=EN
    New
    http://www.europarl.europa.eu/doceo/document/A-4-1999-0078_EN.html
    events/11/docs/0/url
    Old
    http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A5-1999-80&language=EN
    New
    http://www.europarl.europa.eu/doceo/document/A-5-1999-0080_EN.html
    events/12/docs/0/url
    Old
    http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P5-TA-1999-148
    New
    http://www.europarl.europa.eu/doceo/document/TA-5-1999-0148_EN.html
    activities
    • body: CSL meeting_id: 1890 council: Health date: 1995-11-30T00:00:00 type: Council Meeting
    • date: 1998-07-27T00:00:00 docs: url: http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=1998&nu_doc=450 title: COM(1998)0450 type: Legislative proposal published celexid: CELEX:51998PC0450:EN body: EC commission: type: Legislative proposal published
    • date: 1998-09-14T00:00:00 body: EP type: Committee referral announced in Parliament, 1st reading/single reading committees: body: EP responsible: False committee_full: Budgets committee: BUDG body: EP responsible: False committee: DEVE date: 1998-10-28T00:00:00 committee_full: Development and Cooperation rapporteur: group: PSE name: ROCARD Michel body: EP responsible: False committee: ENER date: 1998-10-28T00:00:00 committee_full: ENER Research, Technological Development and Energy rapporteur: group: PPE name: SCAPAGNINI Umberto body: EP responsible: True committee: ENVI date: 1999-09-02T00:00:00 committee_full: Environment, Public Health, Consumer Policy rapporteur: group: PPE-DE name: GROSSETÊTE Françoise body: EP responsible: True committee: ENVI date: 1998-09-22T00:00:00 committee_full: Environment, Public Health and Consumer Protection rapporteur: group: UPE name: CABROL Christian E.A.
    • body: EP committees: body: EP responsible: False committee_full: Budgets committee: BUDG body: EP responsible: False committee: DEVE date: 1998-10-28T00:00:00 committee_full: Development and Cooperation rapporteur: group: PSE name: ROCARD Michel body: EP responsible: False committee: ENER date: 1998-10-28T00:00:00 committee_full: ENER Research, Technological Development and Energy rapporteur: group: PPE name: SCAPAGNINI Umberto body: EP responsible: True committee: ENVI date: 1999-09-02T00:00:00 committee_full: Environment, Public Health, Consumer Policy rapporteur: group: PPE-DE name: GROSSETÊTE Françoise body: EP responsible: True committee: ENVI date: 1998-09-22T00:00:00 committee_full: Environment, Public Health and Consumer Protection rapporteur: group: UPE name: CABROL Christian E.A. docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A4-1999-78&language=EN type: Committee report tabled for plenary, 1st reading/single reading title: A4-0078/1999 date: 1999-02-18T00:00:00 type: Vote in committee, 1st reading/single reading
    • date: 1999-03-09T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=19990309&type=CRE type: Debate in Parliament title: Debate in Parliament type: Decision by Parliament, 1st reading/single reading title: T4-0152/1999 body: EP type: Debate in Parliament
    • date: 1999-06-15T00:00:00 docs: url: http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=1999&nu_doc=298 title: COM(1999)0298 type: Modified legislative proposal published celexid: CELEX:51999PC0298:EN body: EC commission: type: Modified legislative proposal published
    • date: 1999-06-21T00:00:00 body: CSL type: Council Meeting council: Competitiveness (Internal Market, Industry, Research and Space) meeting_id: 2193
    • body: CSL meeting_id: 2202 docs: url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=9616%2F99&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC type: Council position published title: 09616/1/1999 council: Agriculture and Fisheries date: 1999-09-27T00:00:00 type: Council Meeting
    • date: 1999-10-07T00:00:00 body: EP type: Committee referral announced in Parliament, 2nd reading committees: body: EP responsible: True committee: ENVI date: 1999-09-02T00:00:00 committee_full: Environment, Public Health, Consumer Policy rapporteur: group: PPE-DE name: GROSSETÊTE Françoise body: EP responsible: True committee: ENVI date: 1998-09-22T00:00:00 committee_full: Environment, Public Health and Consumer Protection rapporteur: group: UPE name: CABROL Christian E.A.
    • date: 1999-11-25T00:00:00 body: EP type: Vote in committee, 2nd reading committees: body: EP responsible: True committee: ENVI date: 1999-09-02T00:00:00 committee_full: Environment, Public Health, Consumer Policy rapporteur: group: PPE-DE name: GROSSETÊTE Françoise body: EP responsible: True committee: ENVI date: 1998-09-22T00:00:00 committee_full: Environment, Public Health and Consumer Protection rapporteur: group: UPE name: CABROL Christian E.A. docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A5-1999-80&language=EN type: Committee recommendation tabled for plenary, 2nd reading title: A5-0080/1999
    • date: 1999-12-15T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P5-TA-1999-148 type: Decision by Parliament, 2nd reading title: T5-0148/1999 body: EP type: Decision by Parliament, 2nd reading
    • date: 1999-12-16T00:00:00 body: CSL type: Final act signed
    • date: 1999-12-16T00:00:00 body: EP type: End of procedure in Parliament
    • date: 2000-01-22T00:00:00 type: Final act published in Official Journal docs: url: http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32000R0141 title: Regulation 2000/141 url: http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2000:018:TOC title: OJ L 018 22.01.2000, p. 0001
    committees/0
    type
    Responsible Committee
    body
    EP
    associated
    False
    committee_full
    Environment, Public Health, Consumer Policy
    committee
    ENVI
    date
    1999-09-02T00:00:00
    rapporteur
    name: GROSSETÊTE Françoise group: European People's Party (Christian Democrats) and European Democrats abbr: PPE-DE
    committees/0
    body
    EP
    responsible
    False
    committee_full
    Budgets
    committee
    BUDG
    committees/1
    type
    Former Responsible Committee
    body
    EP
    associated
    False
    committee_full
    Environment, Public Health and Consumer Protection
    committee
    ENVI
    date
    1998-09-22T00:00:00
    rapporteur
    name: CABROL Christian E.A. group: Union for Europe Group abbr: UFE
    committees/1
    body
    EP
    responsible
    False
    committee
    DEVE
    date
    1998-10-28T00:00:00
    committee_full
    Development and Cooperation
    rapporteur
    group: PSE name: ROCARD Michel
    committees/2
    type
    Former Committee Opinion
    body
    EP
    associated
    False
    committee_full
    Budgets
    committee
    BUDG
    date
    committees/2
    body
    EP
    responsible
    False
    committee
    ENER
    date
    1998-10-28T00:00:00
    committee_full
    ENER Research, Technological Development and Energy
    rapporteur
    group: PPE name: SCAPAGNINI Umberto
    committees/3
    type
    Former Committee Opinion
    body
    EP
    associated
    False
    committee_full
    Research, Technological Development and Energy
    committee
    ENER
    date
    1998-10-28T00:00:00
    rapporteur
    name: SCAPAGNINI Umberto group: European People's Party (Christian Democrats) abbr: PPE
    committees/3
    body
    EP
    responsible
    True
    committee
    ENVI
    date
    1999-09-02T00:00:00
    committee_full
    Environment, Public Health, Consumer Policy
    rapporteur
    group: PPE-DE name: GROSSETÊTE Françoise
    committees/4
    type
    Former Committee Opinion
    body
    EP
    associated
    False
    committee_full
    Development and Cooperation
    committee
    DEVE
    date
    1998-10-28T00:00:00
    rapporteur
    name: ROCARD Michel group: Party of European Socialists abbr: PES
    committees/4
    body
    EP
    responsible
    True
    committee
    ENVI
    date
    1998-09-22T00:00:00
    committee_full
    Environment, Public Health and Consumer Protection
    rapporteur
    group: UPE name: CABROL Christian E.A.
    council
    • body: CSL type: Council Meeting council: Agriculture and Fisheries meeting_id: 2202 url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=2202*&MEET_DATE=27/09/1999 date: 1999-09-27T00:00:00
    • body: CSL type: Council Meeting council: Competitiveness (Internal Market, Industry, Research and Space) meeting_id: 2193 url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=2193*&MEET_DATE=21/06/1999 date: 1999-06-21T00:00:00
    • body: CSL type: Council Meeting council: Health meeting_id: 1890 url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=1890*&MEET_DATE=30/11/1995 date: 1995-11-30T00:00:00
    docs
    • date: 1998-07-27T00:00:00 docs: url: https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=1998&nu_doc=450 title: EUR-Lex url: https://eur-lex.europa.eu/JOHtml.do?uri=OJ:C:1998:276:SOM:EN:HTML title: OJ C 276 04.09.1998, p. 0007 title: COM(1998)0450 summary: type: Legislative proposal body: EC
    • date: 1998-12-08T00:00:00 docs: title: PE228.612/DEF committee: BUDG type: Committee opinion body: EP
    • date: 1999-01-13T00:00:00 docs: title: PE229.051 type: Committee draft report body: EP
    • date: 1999-01-21T00:00:00 docs: title: PE228.204/DEF committee: DEVE type: Committee opinion body: EP
    • date: 1999-01-27T00:00:00 docs: url: https://dm.eesc.europa.eu/EESCDocumentSearch/Pages/redresults.aspx?k=(documenttype:AC)(documentnumber:0064)(documentyear:1999)(documentlanguage:EN) title: CES0064/1999 url: https://eur-lex.europa.eu/JOHtml.do?uri=OJ:C:1999:101:SOM:EN:HTML title: OJ C 101 12.04.1999, p. 0037 type: Economic and Social Committee: opinion, report body: ESC
    • date: 1999-02-03T00:00:00 docs: title: PE229.051/AM type: Amendments tabled in committee body: EP
    • date: 1999-02-04T00:00:00 docs: title: PE228.976/DEF committee: ENER type: Committee opinion body: EP
    • date: 1999-02-18T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A4-1999-78&language=EN title: A4-0078/1999 url: https://eur-lex.europa.eu/JOHtml.do?uri=OJ:C:1999:175:SOM:EN:HTML title: OJ C 175 21.06.1999, p. 0004 type: Committee report tabled for plenary, 1st reading/single reading body: EP
    • date: 1999-03-09T00:00:00 docs: url: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:C:1999:175:TOC title: OJ C 175 21.06.1999, p. 0017-0066 title: T4-0152/1999 summary: type: Text adopted by Parliament, 1st reading/single reading body: EP
    • date: 1999-06-15T00:00:00 docs: url: https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=1999&nu_doc=298 title: EUR-Lex url: https://eur-lex.europa.eu/JOHtml.do?uri=OJ:C:2000:177E:SOM:EN:HTML title: OJ C 177 27.06.2000, p. 0001 E title: COM(1999)0298 summary: type: Modified legislative proposal body: EC
    • date: 1999-09-27T00:00:00 docs: url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=9616%2F99&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC title: 09616/1/1999 url: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:C:1999:317:TOC title: OJ C 317 04.11.1999, p. 0034 summary: type: Council position body: CSL
    • date: 1999-10-01T00:00:00 docs: url: https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=SECfinal&an_doc=1999&nu_doc=1538 title: EUR-Lex title: SEC(1999)1538 summary: type: Commission communication on Council's position body: EC
    • date: 1999-11-17T00:00:00 docs: title: PE231.753 type: Committee draft report body: EP
    • date: 1999-11-25T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A5-1999-80&language=EN title: A5-0080/1999 url: https://eur-lex.europa.eu/JOHtml.do?uri=OJ:C:2000:194:SOM:EN:HTML title: OJ C 194 11.07.2000, p. 0006 type: Committee recommendation tabled for plenary, 2nd reading body: EP
    • date: 1999-12-15T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P5-TA-1999-148 title: T5-0148/1999 url: https://eur-lex.europa.eu/JOHtml.do?uri=OJ:C:2000:296:SOM:EN:HTML title: OJ C 296 18.10.2000, p. 0035-0091 summary: type: Text adopted by Parliament, 2nd reading body: EP
    • date: 2006-06-20T00:00:00 docs: url: http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/sec/2006/0832/COM_SEC(2006)0832_EN.pdf title: SEC(2006)0832 url: https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=SECfinal&an_doc=2006&nu_doc=832 title: EUR-Lex summary: This Commission staff working document sets out the experience required as a result of the application of Regulation 141/2000/EC on orphan medicinal products and account of the public health benefits obtained. Orphan medicinal products are intended for the diagnosis, prevention or treatment of life-threatening or very rare serious conditions. The report states that the response to the orphan legislation in the EU has far exceeded initial expectations; more than 450 applications have been submitted in the period between April 2000 and April 2005. Of those, more than 260 have been designated and 2 have gone on to receive a marketing authorisation. Although more than 5 years of experience with the Regulation has now been gained, the true impact of the EU orphan initiative on public health will only be revealed progressively as longer term experience is accumulated. Already, more than 1 million patients suffering from orphan diseases in the Community may potentially benefit from these new 22 orphan medicines authorised during the first 5 years of application of Regulation 141/2000/EC. In addition, there is good ground to assume that the legislation has stimulated industrial activity leading to company creation with promising high-tech potential. The full benefits of the EU orphan regulations require optimal synergies between action on Community and on Member State level. Incentives at the European Union level need to be translated into rapid access for patients to the new products throughout the entire Community and they need to be supplemented by incentives at Member States level. In this regard, the past experience was not entirely satisfactory. type: Follow-up document body: EC
    • date: 2016-01-26T00:00:00 docs: title: SWD(2016)0013 summary: This Commission staff working document concerns the fourth inventory of Union and Member State incentives to support research into, and the development and availability of, orphan medicinal products — state of play 2015. This year marks the 15th anniversary of the Orphan Regulation . In that time, there has been impressive progress , in particular as regards generating significant activity by the pharmaceutical industry in this field. After 15 years of implementation and significant advances for patients, the Commission wishes now to take stock of progress in this field. This paper thus represents the fourth version of the inventory. Main conclusions : the Commission has launched a survey to collect information on national measures to support research into, and the development and availability of, OMPs. This information was based on Member States information validated by the relevant national competent authorities in December 2015. The Commission cannot vouch for its accuracy or completeness. R&D support : some Member States have introduced reduced fees for registration and academic clinical trials, tax reductions or waivers, public funding for research and free scientific advice. In France , OMP developers are exempt from certain taxes to be paid by pharmaceutical companies. In the Netherlands , the registration fee can be waived if the medicinal product is already registered in one or more other Member State and the prevalence of the condition is less than 1:150 000. Poland and the United Kingdom , on the other hand, have no specific measures for orphan medicinal products either. Availability of OMPs to patients : as regards measures to support the availability of OMPs to patients, many Member States have confirmed that they are implementing ‘compassionate-use’ programmes to bring unauthorised medicinal products to market. Such programmes are used for individual patients (‘patient programmes’) on the basis of a doctor’s statement or the company can make products available to a group of patients. Reimbursement of the product : the cost of the product may or may not be reimbursed, depending on the Member State. In Greece for instance, orphan drugs covered by a compassionate-use programme for individual patients are reimbursed in full. In Germany , all OMPs are reimbursed directly after market authorisation. The impact of reimbursement on the availability of orphan medicinal products may be a matter of concern in the EU. The budgetary impact of OMPs is expected to rise due to the newly authorised products in the coming years. In this context, it is important to highlight that some Member States have adopted specific measures for the reimbursement of OMPs. Other measures : most Member States reported other measures that they have taken under national plans on rare diseases that cover not only OMPs, but also the prevention (e.g. pre-natal diagnosis) and detection of rare diseases, the exchange of information and cooperation with patients’ organisations. In this context, most confirmed progress for the implementation of the Orphanet database and of centres of expertise for rare diseases and had registers of patients with particular diseases. type: Follow-up document body: EC
    events
    • date: 1995-11-30T00:00:00 type: Resolution/conclusions adopted by Council body: CSL summary: ‘The Council of the European Union, having regard to the Treaty establishing the European Community; whereas, in its Resolution of 30 November 1995 on the integration of health protection requirements in Community policies, the Council considers that the Community must pay particular attention to the impact on health of action proposed in a number of areas, including free movement of goods; whereas action to improve understanding of and address the impact on human health of the free movement of goods, in particular the free movement of medicinal products, should form part of the Community’s overall strategy for action in the field of public health; whereas there are many diseases from which small numbers of people suffer in the Member States and across the Community as a whole; whereas steps are needed to make it easier for patients suffering from those diseases to have access to treatments, in particular by means of so­-called ‘orphan’ drugs, meeting the same criteria as all medicines; whereas, despite the relative infrequency of such diseases, the nature of their treatment and their particular health, economic and social effects are such as to make it advisable to consider them in a European context; whereas the Commission, in its communication of 24 November 1993 on the framework for action in the field for public health, singled out rare diseases as one of eight priority areas for Community action; whereas, in its Decision of 15 December 1994 adopting a specific programme of research and technological development, including demonstration, in the field of biomedicine and health (1994 to 1998), the Council specified rare diseases and orphan drugs as a specific research area (area 4.6), with actions including an inventory of rare disorders; whereas the Commission in its communication of 2 March 1994 on the outlines of an industrial policy for the pharmaceutical sector in the European Community referred to the work to be undertaken, within the field of research on biomedicine and health, on orphan drugs, where research may not be commercially viable; whereas there are certain drugs which are already marketed and have low commercial interest but are of major importance for the treatment of some rare diseases; whereas a common European approach to rare diseases and orphan drugs holds out advantages in epidemiological, public health and economic terms, CALLS ON the Commission, in close cooperation with the Member States and in the light of the guidelines in the Annex, to look into the situation of orphan drugs in Europe and, if necessary, make appropriate proposals with a view to improving access to medicinal products intended particularly for people suffering from rare diseases. Annex Aspects to be considered 1) The definition of an ‘orphan drug’; 2) The definition of a ‘rare disease’, having regard to its prevalence; 3) The criteria for obtaining ‘orphan drug’ status in Europe, establishing conditions for drugs’ inclusion or exclusion, in the light of any changes in the conditions on the basis of which they were classified; 4) Measures using regulatory provisions (including intellectual property aspects) and financial incentives to promote research, development, marketing authorisation and distribution of orphan drugs; 5) Examination of the health impact of a European policy on orphan drugs in the Member States and its economic impact for European industry.’
    • date: 1998-07-27T00:00:00 type: Legislative proposal published body: EC docs: url: https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=1998&nu_doc=450 title: EUR-Lex title: COM(1998)0450 summary:
    • date: 1998-09-14T00:00:00 type: Committee referral announced in Parliament, 1st reading/single reading body: EP
    • date: 1999-02-18T00:00:00 type: Vote in committee, 1st reading/single reading body: EP summary:
    • date: 1999-02-18T00:00:00 type: Committee report tabled for plenary, 1st reading/single reading body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A4-1999-78&language=EN title: A4-0078/1999
    • date: 1999-03-09T00:00:00 type: Debate in Parliament body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=19990309&type=CRE title: Debate in Parliament
    • date: 1999-03-09T00:00:00 type: Decision by Parliament, 1st reading/single reading body: EP docs: title: T4-0152/1999 summary:
    • date: 1999-06-15T00:00:00 type: Modified legislative proposal published body: EC docs: url: https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=1999&nu_doc=298 title: EUR-Lex title: COM(1999)0298 summary:
    • date: 1999-09-27T00:00:00 type: Council position published body: CSL docs: url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=9616%2F99&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC title: 09616/1/1999 summary:
    • date: 1999-10-07T00:00:00 type: Committee referral announced in Parliament, 2nd reading body: EP
    • date: 1999-11-25T00:00:00 type: Vote in committee, 2nd reading body: EP
    • date: 1999-11-25T00:00:00 type: Committee recommendation tabled for plenary, 2nd reading body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A5-1999-80&language=EN title: A5-0080/1999
    • date: 1999-12-15T00:00:00 type: Decision by Parliament, 2nd reading body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P5-TA-1999-148 title: T5-0148/1999 summary:
    • date: 1999-12-16T00:00:00 type: Final act signed body: CSL
    • date: 1999-12-16T00:00:00 type: End of procedure in Parliament body: EP
    • date: 2000-01-22T00:00:00 type: Final act published in Official Journal docs: title: Regulation 2000/141 url: https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32000R0141 title: OJ L 018 22.01.2000, p. 0001 url: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2000:018:TOC
    other
    • body: CSL type: Council Meeting council: Former Council configuration
    procedure/dossier_of_the_committee
    Old
    ENVI/5/12115
    New
    • ENVI/5/12115
    procedure/final/url
    Old
    http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32000R0141
    New
    https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32000R0141
    procedure/subject
    Old
    • 4.20.04 Pharmaceutical products and industry
    New
    4.20.01
    Medicine, diseases
    4.20.02
    Medical research
    4.20.04
    Pharmaceutical products and industry
    procedure/title
    Old
    Pharmaceutical industry: marketing and Community procedure for designating orphan medicinal products
    New
    Orphan medicinal products
    links/European Commission/title
    Old
    PreLex
    New
    EUR-Lex
    activities/2/committees/2/rapporteur/0/mepref
    Old
    525efb25b819f23aa7000000
    New
    53ba7f69b819f24b3300016f
    activities/3/committees/2/rapporteur/0/mepref
    Old
    525efb25b819f23aa7000000
    New
    53ba7f69b819f24b3300016f
    committees/2/rapporteur/0/mepref
    Old
    525efb25b819f23aa7000000
    New
    53ba7f69b819f24b3300016f
    activities
    • body: CSL meeting_id: 1890 council: Health date: 1995-11-30T00:00:00 type: Council Meeting
    • date: 1998-07-27T00:00:00 docs: url: http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=1998&nu_doc=450 title: COM(1998)0450 type: Legislative proposal published celexid: CELEX:51998PC0450:EN body: EC type: Legislative proposal published commission:
    • date: 1998-09-14T00:00:00 body: EP type: Committee referral announced in Parliament, 1st reading/single reading committees: body: EP responsible: False committee_full: Budgets committee: BUDG body: EP responsible: False committee: DEVE date: 1998-10-28T00:00:00 committee_full: Development and Cooperation rapporteur: group: PSE name: ROCARD Michel body: EP responsible: False committee: ENER date: 1998-10-28T00:00:00 committee_full: ENER Research, Technological Development and Energy rapporteur: group: PPE name: SCAPAGNINI Umberto body: EP responsible: True committee: ENVI date: 1999-09-02T00:00:00 committee_full: Environment, Public Health, Consumer Policy rapporteur: group: PPE-DE name: GROSSETÊTE Françoise body: EP responsible: True committee: ENVI date: 1998-09-22T00:00:00 committee_full: Environment, Public Health and Consumer Protection rapporteur: group: UPE name: CABROL Christian E.A.
    • body: EP committees: body: EP responsible: False committee_full: Budgets committee: BUDG body: EP responsible: False committee: DEVE date: 1998-10-28T00:00:00 committee_full: Development and Cooperation rapporteur: group: PSE name: ROCARD Michel body: EP responsible: False committee: ENER date: 1998-10-28T00:00:00 committee_full: ENER Research, Technological Development and Energy rapporteur: group: PPE name: SCAPAGNINI Umberto body: EP responsible: True committee: ENVI date: 1999-09-02T00:00:00 committee_full: Environment, Public Health, Consumer Policy rapporteur: group: PPE-DE name: GROSSETÊTE Françoise body: EP responsible: True committee: ENVI date: 1998-09-22T00:00:00 committee_full: Environment, Public Health and Consumer Protection rapporteur: group: UPE name: CABROL Christian E.A. docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A4-1999-78&language=EN type: Committee report tabled for plenary, 1st reading/single reading title: A4-0078/1999 date: 1999-02-18T00:00:00 type: Vote in committee, 1st reading/single reading
    • date: 1999-03-09T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=19990309&type=CRE type: Debate in Parliament title: Debate in Parliament type: Decision by Parliament, 1st reading/single reading title: T4-0152/1999 body: EP type: Debate in Parliament
    • date: 1999-06-15T00:00:00 docs: url: http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=1999&nu_doc=298 title: COM(1999)0298 type: Modified legislative proposal published celexid: CELEX:51999PC0298:EN body: EC type: Modified legislative proposal published commission:
    • date: 1999-06-21T00:00:00 body: CSL type: Council Meeting council: Competitiveness (Internal Market, Industry, Research and Space) meeting_id: 2193
    • body: CSL meeting_id: 2202 docs: url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=9616%2F99&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC type: Council position published title: 09616/1/1999 council: Agriculture and Fisheries date: 1999-09-27T00:00:00 type: Council Meeting
    • date: 1999-10-07T00:00:00 body: EP type: Committee referral announced in Parliament, 2nd reading committees: body: EP responsible: True committee: ENVI date: 1999-09-02T00:00:00 committee_full: Environment, Public Health, Consumer Policy rapporteur: group: PPE-DE name: GROSSETÊTE Françoise body: EP responsible: True committee: ENVI date: 1998-09-22T00:00:00 committee_full: Environment, Public Health and Consumer Protection rapporteur: group: UPE name: CABROL Christian E.A.
    • date: 1999-11-25T00:00:00 body: EP type: Vote in committee, 2nd reading committees: body: EP responsible: True committee: ENVI date: 1999-09-02T00:00:00 committee_full: Environment, Public Health, Consumer Policy rapporteur: group: PPE-DE name: GROSSETÊTE Françoise body: EP responsible: True committee: ENVI date: 1998-09-22T00:00:00 committee_full: Environment, Public Health and Consumer Protection rapporteur: group: UPE name: CABROL Christian E.A. docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A5-1999-80&language=EN type: Committee recommendation tabled for plenary, 2nd reading title: A5-0080/1999
    • date: 1999-12-15T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P5-TA-1999-148 type: Decision by Parliament, 2nd reading title: T5-0148/1999 body: EP type: Decision by Parliament, 2nd reading
    • date: 1999-12-16T00:00:00 body: CSL type: Final act signed
    • date: 1999-12-16T00:00:00 body: EP type: End of procedure in Parliament
    • date: 2000-01-22T00:00:00 type: Final act published in Official Journal docs: url: http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32000R0141 title: Regulation 2000/141 url: http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2000:018:TOC title: OJ L 018 22.01.2000, p. 0001
    committees
    • body: EP responsible: False committee_full: Budgets committee: BUDG
    • body: EP responsible: False committee: DEVE date: 1998-10-28T00:00:00 committee_full: Development and Cooperation rapporteur: group: PSE name: ROCARD Michel
    • body: EP responsible: False committee: ENER date: 1998-10-28T00:00:00 committee_full: ENER Research, Technological Development and Energy rapporteur: group: PPE name: SCAPAGNINI Umberto
    • body: EP responsible: True committee: ENVI date: 1999-09-02T00:00:00 committee_full: Environment, Public Health, Consumer Policy rapporteur: group: PPE-DE name: GROSSETÊTE Françoise
    • body: EP responsible: True committee: ENVI date: 1998-09-22T00:00:00 committee_full: Environment, Public Health and Consumer Protection rapporteur: group: UPE name: CABROL Christian E.A.
    links
    European Commission
    other
    • body: CSL type: Council Meeting council: Former Council configuration
    procedure
    dossier_of_the_committee
    ENVI/5/12115
    reference
    1998/0240(COD)
    subtype
    Legislation
    legal_basis
    EC Treaty (after Amsterdam) EC 095
    stage_reached
    Procedure completed
    instrument
    Regulation
    title
    Pharmaceutical industry: marketing and Community procedure for designating orphan medicinal products
    type
    COD - Ordinary legislative procedure (ex-codecision procedure)
    final
    subject
    4.20.04 Pharmaceutical products and industry